{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["BMS-986365","CC1083611","CC1083610"]],"indication":"metastatic castration-resistant prostate cancer","name":"CC-94676-PCA-001","nct_id":"NCT04428788","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cc-94676-pca-001-nct04428788. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Administration of CC-94676, CC1083611, and CC1083610","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-10-28","type":"ACTUAL"},"conditions":["Prostatic Neoplasms"],"enrollment":{"count":131,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CC-94676","otherNames":["BMS-986365"],"type":"DRUG"},{"name":"CC1083611","otherNames":["BMS-986409"],"type":"DRUG"},{"name":"CC1083610","otherNames":["BMS-986410"],"type":"DRUG"}],"last_update":"2025-12-22","lead_sponsor":"Celgene","official_title":"A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-10-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria","timeFrame":"From the time of consent at screening until 28 days after thesubject discontinues study treatment."},{"measure":"Dose-limiting toxicity (DLT)","timeFrame":"Up to 35 days"},{"measure":"Non-tolerated dose (NTD)","timeFrame":"Up to 35 days"},{"measure":"Maximum tolerated dose (MTD)","timeFrame":"Up to 35 days"}],"references":[{"citation":"Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jan;36(1):76-88. doi: 10.1016/j.annonc.2024.09.005. Epub 2024 Sep 16.","pmid":"39293515","type":"DERIVED"}],"start_date":{"date":"2020-06-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04428788"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cc-94676-pca-001-nct04428788"}